Living & Managing
Understanding Soliqua 100/33™and Xultophy 100/3.6™: Once-Daily Injectables
Learning about: Soliqua 100/33™ and Xultophy 100/3.6™: the new once-daily injectable GLP-1 receptor agonist/basal insulin combination pens Soliqua 100/33 and Xultophy 100/3.6 are two new injectable combination products approved by the U.S. Food and Drug Administration (FDA) in November of 2016. They are used for the treatment of type 2 diabetes (T2DM) in adults who are not well-controlled on metformin or oral medications and either a basal (long-acting) insulin or a glucagon-like peptide 1 receptor...
Learning About Diabulimia
Learning About Diabulimia Most people are familiar with eating disorders such as anorexia, bulimia and binge eating disorder, but few are familiar with an eating disorder that is unique to patients with type 1 diabetes (T1DM). ED-DMT1, or what the media has dubbed “diabulimia,” is an eating disorder where patients with T1DM will purposely stop taking or significantly reduce their insulin doses to lose weight. Without enough insulin,patients with T1DM will lose calories through the...
Understanding What You Need To Know About Albuminuria And Diabetic Kidney Disease
Underatnding What You Need To Know About Albuminuria And Diabetic Kidney Disease There are several disorders that are associated with diabetes: high blood pressure, high cholesterol, obesity, heart disease and kidney disease. According to the American Diabetes Association (ADA) Guidelines, kidney disease occurs in 20-40% of patients with diabetes and is the leading cause of end-stage renal disease meaning.  When you have end-stage renal disease that means that the kidneys are functioning less than 10%....
1 2 3 4 >

Global Translator

Featured Recent Comments